<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163525</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00-0025</org_study_id>
    <nct_id>NCT02163525</nct_id>
  </id_info>
  <brief_title>Post Market TRUST - U.S.A. Study</brief_title>
  <official_title>The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acessa Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acessa Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Post Market study is being conducted to compare the direct and indirect cost of three
      approaches (GFA, myomectomy, and uterine artery embolization) for the treatment of
      symptomatic uterine fibroids. In addition, data from this study is being used to satisfy the
      requirements of the United States Food and Drug Administration's 522 (post market
      surveillance) order.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to 1) evaluate the economic burden, safety and outcomes of three
      uterine-conserving treatment alternatives for symptomatic uterine fibroids: myomectomy,
      uterine artery embolization (UAE), and global fibroid ablation (GFA) using the Acessa™
      System, and 2) meet the requirements of the U.S. Food and Drug Administration's 522 Order for
      post market surveillance In this study, subjects who have symptomatic uterine fibroids will
      be randomized to one of three uterine-conserving treatments based on the local standard of
      care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare direct cost of GFA compared to those of myomectomy and UAE</measure>
    <time_frame>3 months post procedure</time_frame>
    <description>To compare medical, surgical, and hospitalization costs (including procedural complication costs) of Global Fibroid Ablation (GFA) compared to those of Myomectomy and Uterine Artery Embolization (UAE)at 3 months post procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare rates of acute and near-term serious complications to the acute and near-term treatment-related serious adverse events of pivotal study.</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Overall rates of acute (within 48 hours post procedure) and near-term (between 2 and 30 days post procedure) serious complications in all GFA subjects compared to the acute and near-term treatment-related serious adverse event rates in the pivotal study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the incidence and cost of post discharge procedure-related complications and reinterventions</measure>
    <time_frame>60 months</time_frame>
    <description>Safety measures will be assessed by comparing the complication and reintervention rate for all three alternatives (GFA, Myomectomy, UAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess factors that influence indirect costs of the three treatment alternatives</measure>
    <time_frame>60 months</time_frame>
    <description>Compare incidence costs of post discharge procedure-related complications and re-interventions we well as indirect cost factors defined as days to return-to-work, return to normal activities of daily living, and cost of care up to 60 months post discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Uterine Fibroid Symptom Severity and Quality of Life (UFS-QoL) pre-treatment to post treatment in all treatment groups</measure>
    <time_frame>60 months</time_frame>
    <description>To compare fibroid symptom severity and quality of life scores at 3, 6, 12, 24, 36, 48, and 60 months post procedure as compared to baseline using the Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) assessment tool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess subjects menstrual bleeding using the MIQ</measure>
    <time_frame>60 months</time_frame>
    <description>Compare subjects menstrual bleeding pre-treatment and up to 3, 6, 12, 24, 36, 48, and 60 months post treatment using the Menorrhagia Impact Questionnaire (MIQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess subject's satisfaction with her treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the subject's satisfaction with her assigned procedure at 12 months post procedure using the Overall Treatment Effect questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the subject's general health outcome</measure>
    <time_frame>60 months post procedure</time_frame>
    <description>General health outcome evaluation at 3, 6, 12, 24, 36, 48, and 60 months post procedure as compared to baseline using the EuroQol (EQ-5D), a standardized instrument for use as a measure of health outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the incidence of serious complications per investigator-surgeon during training and post training.</measure>
    <time_frame>60 months</time_frame>
    <description>The incidence of acute and near-term serious complications following the GFA cases will also be analyzed by investigator-surgeon during the training and post training periods..</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Symptomatic Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Ablation vs Embolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ablation vs Myomectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Global Fibroid Ablation (GFA)</intervention_name>
    <description>GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.</description>
    <arm_group_label>Ablation vs Embolization</arm_group_label>
    <arm_group_label>Ablation vs Myomectomy</arm_group_label>
    <other_name>GFA</other_name>
    <other_name>Radiofrequency ablation</other_name>
    <other_name>RFA</other_name>
    <other_name>Radiofrequency volumetric fibroid ablation</other_name>
    <other_name>Acessa procedure</other_name>
    <other_name>Acessa treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Abdominal or Laparoscopic Myomectomy</intervention_name>
    <description>Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.</description>
    <arm_group_label>Ablation vs Myomectomy</arm_group_label>
    <other_name>Myomectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Uterine Artery Embolization (UAE)</intervention_name>
    <description>UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.</description>
    <arm_group_label>Ablation vs Embolization</arm_group_label>
    <other_name>UAE</other_name>
    <other_name>Uterine Fibroid Embolization</other_name>
    <other_name>UFE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are ≥ 18 years old and menstruating

          -  Have symptomatic uterine fibroids

          -  Have a uterine size ≤ 16 gestational weeks as determined by pelvic exam

          -  Have all fibroids that are less than 10 cm in any diameter

          -  Desire uterine conservation

          -  Have had a normal Pap smear within the past 36 months defined as &quot;no untreated
             cervical malignancy or dysplasia.&quot;

          -  Are willing and able to comply with all study tests, procedures, and assessment tools

          -  Are capable of providing informed consent.

        Exclusion Criteria:

          -  Have contraindications for laparoscopic surgery and/or general anesthesia.

          -  Are expected to be high risk for, or are known to have, significant intra-abdominal
             adhesions (defined as adhesions that would require extensive dissection to mobilize
             and view all surfaces of the uterus)

          -  Patients requiring major elective concomitant procedures (e.g., hernia repair)

          -  Are pregnant or lactating

          -  Have taken any depot gonadotropin releasing hormone (GnRh) agonist within three months
             prior to the screening procedures

          -  Have an implanted intrauterine or fallopian tube device for contraception that cannot
             or will not be removed at least 10 days prior to treatment

          -  Have chronic pelvic pain known to not be due to uterine fibroids

          -  Have known or suspected endometriosis Stage 3 or 4, adenomyosis

          -  Have active or history of pelvic inflammatory disease

          -  Have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the
             past five years

          -  Have had pelvic radiation

          -  Have a non-uterine pelvic mass over 3 cm

          -  Have a cervical myoma

          -  Have one or more completely intracavitary submucous fibroids (Type 0) or only Type 0/1
             submucous fibroids that are better treated via hysteroscopic methods

          -  In the medical judgment of the investigator should not participate in the study

          -  Are not willing to be randomized to treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Eisenstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janine Little, BA</last_name>
    <email>jlittle@acessahealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Kemp, BS,MA,RT(R)</last_name>
    <email>lkemp@acessahealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ria Jain, BS</last_name>
      <phone>310-206-6049</phone>
      <email>riajain@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anna Amamchyan, BS</last_name>
      <phone>310-825-5255</phone>
      <email>aamamchyan@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steve P Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aspen Surgery Center/John Muir Hospital</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Pascualy, P.A.</last_name>
      <phone>925-478-7189</phone>
      <email>julie.truststudy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yaron Friedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald Galen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-3360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Miller, LPN</last_name>
      <phone>706-446-0014</phone>
      <email>JMILLER7@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Connie Edwards, RN</last_name>
      <phone>706-446-0014</phone>
      <email>COEDWARDS@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kelli Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin Latif, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chad Ray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manish Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine and Biological Sciences</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Greenberg, MD</last_name>
      <phone>617-983-7003</phone>
      <email>jagreenberg@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>James Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Eisenstein, MD</last_name>
      <phone>248-661-7381</phone>
      <email>Deisens1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>David Eisenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Kumar, MPH</last_name>
      <phone>585-275-9204</phone>
      <email>Divya_Kumar@URMC.Rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bala Bhagavath, MD</last_name>
      <phone>585-487-3445</phone>
    </contact_backup>
    <investigator>
      <last_name>Bala Bhagavath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Fertility Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>INOVA</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Mishra, MD</last_name>
      <phone>703-776-4600</phone>
      <email>rashmi.mishra@inova.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Marull</last_name>
      <phone>703-776-4345</phone>
      <email>stephanie.marull@inova.org</email>
    </contact_backup>
    <investigator>
      <last_name>S. Abbās Shobeiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002 Feb;99(2):290-300.</citation>
    <PMID>11814511</PMID>
  </reference>
  <reference>
    <citation>Viswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, Lux LJ, Lohr KN. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep). 2007 Jul;(154):1-122. Review.</citation>
    <PMID>18288885</PMID>
  </reference>
  <reference>
    <citation>Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Implementation of advanced laparoscopic surgery in gynecology: national overview of trends. J Minim Invasive Gynecol. 2010 Jul-Aug;17(4):487-92. doi: 10.1016/j.jmig.2010.03.010. Epub 2010 May 14.</citation>
    <PMID>20471917</PMID>
  </reference>
  <reference>
    <citation>Holzer A, Jirecek ST, Illievich UM, Huber J, Wenzl RJ. Laparoscopic versus open myomectomy: a double-blind study to evaluate postoperative pain. Anesth Analg. 2006 May;102(5):1480-4.</citation>
    <PMID>16632830</PMID>
  </reference>
  <reference>
    <citation>Parker WH, Iacampo K, Long T. Uterine rupture after laparoscopic removal of a pedunculated myoma. J Minim Invasive Gynecol. 2007 May-Jun;14(3):362-4.</citation>
    <PMID>17478371</PMID>
  </reference>
  <reference>
    <citation>Banas T, Klimek M, Fugiel A, Skotniczny K. Spontaneous uterine rupture at 35 weeks' gestation, 3 years after laparoscopic myomectomy, without signs of fetal distress. J Obstet Gynaecol Res. 2005 Dec;31(6):527-30.</citation>
    <PMID>16343253</PMID>
  </reference>
  <reference>
    <citation>Moss JG, Cooper KG, Khaund A, Murray LS, Murray GD, Wu O, Craig LE, Lumsden MA. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG. 2011 Jul;118(8):936-44. doi: 10.1111/j.1471-0528.2011.02952.x. Epub 2011 Apr 12.</citation>
    <PMID>21481151</PMID>
  </reference>
  <reference>
    <citation>Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol. 2008 Jan-Feb;31(1):73-85. Epub 2007 Oct 18.</citation>
    <PMID>17943348</PMID>
  </reference>
  <reference>
    <citation>Manyonda IT, Bratby M, Horst JS, Banu N, Gorti M, Belli AM. Uterine artery embolization versus myomectomy: impact on quality of life--results of the FUME (Fibroids of the Uterus: Myomectomy versus Embolization) Trial. Cardiovasc Intervent Radiol. 2012 Jun;35(3):530-6. doi: 10.1007/s00270-011-0228-5. Epub 2011 Jul 20.</citation>
    <PMID>21773858</PMID>
  </reference>
  <reference>
    <citation>Carls GS, Lee DW, Ozminkowski RJ, Wang S, Gibson TB, Stewart E. What are the total costs of surgical treatment for uterine fibroids? J Womens Health (Larchmt). 2008 Sep;17(7):1119-32. doi: 10.1089/jwh.2008.0456.</citation>
    <PMID>18687032</PMID>
  </reference>
  <reference>
    <citation>Nash K, Feinglass J, Zei C, Lu G, Mengesha B, Lewicky-Gaupp C, Lin A. Robotic-assisted laparoscopic myomectomy versus abdominal myomectomy: a comparative analysis of surgical outcomes and costs. Arch Gynecol Obstet. 2012 Feb;285(2):435-40. doi: 10.1007/s00404-011-1999-2. Epub 2011 Jul 22.</citation>
    <PMID>21779774</PMID>
  </reference>
  <reference>
    <citation>Al-Fozan H, Dufort J, Kaplow M, Valenti D, Tulandi T. Cost analysis of myomectomy, hysterectomy, and uterine artery embolization. Am J Obstet Gynecol. 2002 Nov;187(5):1401-4.</citation>
    <PMID>12439538</PMID>
  </reference>
  <reference>
    <citation>Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010 Dec;26(12):2745-55. doi: 10.1185/03007995.2010.532200. Epub 2010 Nov 3.</citation>
    <PMID>21043553</PMID>
  </reference>
  <reference>
    <citation>Hartung J, Knapp G. On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med. 2001 Jun 30;20(12):1771-82.</citation>
    <PMID>11406840</PMID>
  </reference>
  <reference>
    <citation>Robles R, Aguirre VA, Argueta AI, Guerrero MR. Laparoscopic radiofrequency volumetric thermal ablation of uterine myomas with 12 months of follow-up. Int J Gynaecol Obstet. 2013 Jan;120(1):65-9. doi: 10.1016/j.ijgo.2012.07.023. Epub 2012 Oct 14.</citation>
    <PMID>23073229</PMID>
  </reference>
  <reference>
    <citation>Garza Leal JG, Hernandez Leon I, Castillo Saenz L, Lee BB. Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 Ablation System. J Minim Invasive Gynecol. 2011 May-Jun;18(3):364-71. doi: 10.1016/j.jmig.2011.02.006.</citation>
    <PMID>21545960</PMID>
  </reference>
  <reference>
    <citation>Macer JA. For uterine-sparing fibroid treatment, consider laparoscopic ultrasound-guided radiofrequency ablation. obmanagement.com Vol 25 No. 11 November 2013</citation>
  </reference>
  <results_reference>
    <citation>Chudnoff SG, Berman JM, Levine DJ, Harris M, Guido RS, Banks E. Outpatient procedure for the treatment and relief of symptomatic uterine myomas. Obstet Gynecol. 2013 May;121(5):1075-82. doi: 10.1097/AOG.0b013e31828b7962.</citation>
    <PMID>23635746</PMID>
  </results_reference>
  <results_reference>
    <citation>Guido RS, Macer JA, Abbott K, Falls JL, Tilley IB, Chudnoff SG. Radiofrequency volumetric thermal ablation of fibroids: a prospective, clinical analysis of two years' outcome from the Halt trial. Health Qual Life Outcomes. 2013 Aug 13;11:139. doi: 10.1186/1477-7525-11-139.</citation>
    <PMID>23941588</PMID>
  </results_reference>
  <results_reference>
    <citation>Berman JM, Guido RS, Garza Leal JG, Pemueller RR, Whaley FS, Chudnoff SG; Halt Study Group. Three-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):767-74. doi: 10.1016/j.jmig.2014.02.015. Epub 2014 Mar 5.</citation>
    <PMID>24613404</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibroids</keyword>
  <keyword>Myomas</keyword>
  <keyword>leiomyomata</keyword>
  <keyword>menorrhagia</keyword>
  <keyword>Acessa Procedure</keyword>
  <keyword>Radiofrequency Ablation (RFA)</keyword>
  <keyword>GFA</keyword>
  <keyword>Acessa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

